CURRICULUM VITAE

«NWCRC Home»

 

Name:                           Arifulla Khan, MD

 

Birth:                            Bangalore, India

                                     February 3, 1953

 

Citizenship:                 U.S. (Naturalized, 1988)

 

Marital Status: Married to Christine with two children

 

Address:                      NorthWest Clinical Research Center

                                    1951 152nd Place NE Suite 200

                                    Bellevue, WA 98007

                                    Phone:   (425) 453-0404

                                    Fax:       (425) 453-1033

                                    E-mail:   akhan@nwcrc.net

 

Education:                   National College (1967-1969)

                                    Bangalore Medical College (1969-1975)

                                    Bangalore University, India

 

Qualifications: MBBS, Bangalore University, India, 1975

                                    ECFMG, 1976

                                    Visa Qualifying Examination, 1979

                                    FLEX, 1982

                                    American Board of Psychiatry and Neurology, 1987

 

Licensure:                   Indian Medical Council (Karnataka State) #14, 297

                                    Washington State - #21545

                                   

Clinical and Academic Experience:

 

9/75 - 9/76                   Intern, Victoria and Combined Hospitals

                                    Bangalore University, India

 

9/77 - 9/81                   Psychiatric Registrar

                                    Christchurch Clinical School

                                    University of Otago

                                    Christchurch, New Zealand

 


10/81 - 6/84                 Resident/Chief Resident

                                    Department of Psychiatry

                                    University of Connecticut

                                    Farmington, Connecticut

 

10/84 - 8/87                 Medical Director

                                    Voluntary Psychiatric Inpatient Unit

                                    Harborview Medical Center, Seattle, WA

 

11/84 - 6/90                 Assistant Professor, Department of Psychiatry

                                    University of Washington, Seattle, WA

 

9/87 - 6/88                   Medical Director, Inpatient Psychiatry Service

                                    Harborview Medical Center, Seattle, WA

 

6/88 -                           Examiner/Senior Examiner, American Board of Psychiatry

Present                        and Neurology (Part II)

 

7/88 - 1/95                   Medical Director, Inpatient Psychiatry Service

                                    University of Washington Medical Center

                                    Seattle, WA

 

7/90 - 6/95                   Associate Professor, Department of Psychiatry

                                    University of Washington, Seattle, WA

 

7/92 - 1/95                   Associate Medical Director

                                    University of Washington Medical Center

                                    Seattle, WA

 

4/95 -                           Medical Director

Present                         Northwest Clinical Research Center

                                    Northwest Medical Education, Inc

                                    Bellevue, WA

 

6/95 – 01/06                Medical Staff at Overlake Hospital Medical Center

                                    1035 – 116th Ave.NE

                                    Bellevue, WA 98004

 

6/95-                            Research Affiliate/Consultant and Courtesy Medical Staff

Present                         BHC Fairfax Hospital

                                    10200 NE 132nd St.

                                    Kirkland, WA 98034

 

 

 

2/97-12/02                   Clinical Associate Professor

                                    Department of Psychiatry and Behavioral Sciences

                                    University of Washington, Seattle, WA

 

10/00 -                         Adjunct Associate Professor

11/2005                       Department of Psychiatry and behavioral Sciences

                                    Duke University School of Medicine, Durham, NC

 

12/05 -                         Adjunct Professor

Present                         Department of Psychiatry and Behavioral Sciences

                                    Duke University School of Medicine, Durham, NC

 

2009-present               Medical Director

                                    Columbia Northwest Pharmaceuticals, LLC

                                    Bellevue, Washington

 

2010-present               Medical Director        

                                    Rhine Pharmaceuticals, LLC

                                    Bellevue, Washington

 

Grants, Awards, and Research Experience:

 

6/84                             Sandoz Award for superior academic achievement

                                    Department of Psychiatry, University of Connecticut

 

9/84 - 2/90                   Clinical psychopharmacology sub-investigator in depressive disorders,

                                    Psychiatric Research Unit, Harborview Medical Center

                                    and University of Washington (PI - D. Dunner, MD)

 

3/85                             Principal Investigator, Biomedical Research Support Grant from

                                    University of Washington for the study of treatment response to

                                    various antidepressants and placebo

 

8/87                             Travel fellowship from the American College of

                                    Neuropsychopharmacology (ACNP)

 

10/88                           Principal Investigator, ECT vs. pharmacotherapy in psychotic         

                                    depression (R01 application, approved, not funded)

 

1/89-12/89                   Co-Investigator, Sleep changes in Early Alzheimer’s Disease

                                    (PI- Patricia Prinz, PhD, MHR01-33688)

 

3/91 - 10/91                 Principal Investigator, The Washington Institute for Mental Illness

                                    Research and Training Grant for TRH in ECT and ECS

 

1/92 - 12/92                 Principal Investigator, The Alcohol and Drug Abuse Institute,

                                    University of Washington, Grant for TRH in cognitively impaired

                                    alcoholics

 

6/94                             Principal Investigator, Treatment of Depression Using Low-level

                                    Electrical Current or Alternating Magnetic Fields (patent filed)

 

3/90 -                           Principal Investigator 

Present                        Phase I, II, III and IV Psychopharmacology Studies in depression, treatment resistant depression, generalized anxiety disorder, insomnia, bipolar mood disorder, schizophrenia, Alzheimer’s disease, migraine, irritable bowel syndrome, post traumatic stress disroder, social anxiety disorder, attention deficit/hyperactivity disorder, female hypoactive sexual desire disorder, pediatric depression, pediatric bipolar mood disorder, pediatric attention deficit/hyperactivity disorder, pain, obsessive compulsive disorder, geriatric depression, geriatric generalized anxiety disorder 

 

3/01- present               Extramural Reviewer, SBIR proposals, Ad Hoc committees, National Institute of Mental Health

 

3/05                             Thomson Essential Science Indicators recognizing two publications

                                    (#66 and #81) receiving top 1% of citations between 2000 and 2004

                                    suggesting ‘extraordinary career accomplishment’ 

 

11/06 -                         Member of the Board

Present                         American College of Clinical Psychopharmacology

 

01/10 -                         Fellow

Present                         American Psychiatric Association

 

11/10                           Columbia Pharmaceuticals, Qualifying Therapeutic Discover Program Grant under the Patient Protection and Affordable Care Act for Treatment of Suicidality in Depressed Patients Using Lithium in Combination with SSRI Therapy, $244,479.25

 

11/10                           Columbia Pharmaceuticals, Qualifying Therapeutic Discover Program Grant under the Patient Protection and Affordable Care Act  Grant for Treatment of PTSD Using Carvedilol, $244,479.25

 

11/10                           Rhine Pharmaceuticals, Qualifying Therapeutic Discover Program Grant under the Patient Protection and Affordable Care Act for Synthesis and Development of the Bupropion r-enantiomer, $244,479.25

 

Academic Memberships and Related Activities:

 

                                    American Medical Association

                                    American Psychiatric Association

                                    American College of Clinical Psychopharmacology

                                    King County Medical Society

 

 

Journal Reviewer:

                                    Acta Psychiatrica Scandinavica

                                    American Journal of Cardiology

                                    American Journal of Psychiatry

                                    Annals of General Hospital Psychiatry

                                    Archives of General Psychiatry

                                    Biomed Central

                                    Bipolar Disorders

                                    Biological Psychiatry

                                    BMC Medicine

                                    British Medical Journal (BMJ)

                                    CNS Neuroscience and Therapeutics

                                    Controlled Clinical Trials (Elsevier)

                                    Convulsive Therapy

                                    Depression and Anxiety

                                    Expert Opinion on Pharmacotherapy

                                    European Psychiatry

                                    Human Psychopharmacology: Clinical and Experimental

                                    International Journal of Neuropsychopharmacology

                                    Journal of Affective Disorders

                                    Journal of the American Medical Association (JAMA)

                                    Journal of Clinical Psychiatry

                                    Journal of Clinical Psychopharmacology

                                    Journal of General Internal Medicine

                                    Journal of Mind Body Regulation

                                    Journal of Nervous and Mental Disease

                                    Journal of Neural Transmission

                                    Journal of Psychiatric Research

                                    Journal of Schizophrenia and Related Psychoses

                                    Journal of Studies on Alcohol and Drugs

                                    Lancet

                                    Neuropsychopharmacology

                                    Progress in Neuro-psychopharmacology and Biological Research

                                    Psychiatry Research

                                    Psychological Medicine

 

Publications:

 

1.  Khan A, Joyce P, Jones A.  Benzodiazepine withdrawal syndromes.  New Zealand Medical Journal 92(665): 94-96, 1980. 

2.  Khan A, Hornblow A, Walshe JWB.  Benzodiazepine dependence: a general practice  survey.  New Zealand Medical Journal 94(687): 19-21, 1981. 

3.  Joyce P, Khan A, Jones A.  The revolving door patient.  Comprehensive Psychiatry

            22(4): 397-403, 1981. 

4.  Khan A, Ciraulo DA, Nelson WH, Becker JT, Nies A, Jaffe J.  Dexamethasone suppression test in recently detoxified alcoholics: clinical implications.  Journal of Clinical Psychopharmacology 4(2): 94-97, 1984. 

5.  Nelson WH, Khan A Orr WW.  Delusional depression: phenomenology, neuroendocrine

            function, and tricyclic antidepressant response.  Journal of Affective Disorders 6(3-4):

            297-306, 1984. 

6.  Nelson WH, Khan A, Orr WW, Tamragouri RN.  The dexamethasone suppression test:

            interaction of diagnosis, sex and age in psychiatric patients.  Biological Psychiatry 19(9): 1293-1304, 1984. 

7.  Reik L, Smith L, Khan A, Nelson WH.  Demyelinating encephalopathy in Lyme disease. 

            Neurology 35(2): 267-269, 1985. 

8.  Khan A, Jaffe J, Nelson WH, Morrison B.  Resolution of neuroleptic malignant syndrome

            with dantrolene sodium: case report.  Journal of Clinical Psychiatry 46(6): 244-246, 1985. 

9.  Khan A, Nies A, Johnson GA, Becker JT.  Plasma catecholamines and ECT.  Biological

            Psychiatry 20(7): 799-804, 1985. 

10. Nelson WH, Sullivan P, Khan A, Tamragouri RN.  The effects of age on dexamethasone

            suppression test results in alcoholic patients.  American Journal of   Psychiatry 143(2):

            237-239, 1986. 

11. Khan A, Lee E, Dager S, Hyde T, Raisys V, Avery D, Dunner DL.  Platelets MAO activity in anxiety and depression.  Biological Psychiatry 21(8-9): 847-849, 1986. 

12.  Dager S, Khan A, Comess K, Raisys V, Dunner DL.  Mitral valve abnormalities and catecholamine activity in anxious patients.  Psychiatry Research 20: 13-18, 1987. 

13.  Khan A, Cohen S, Chiles J, Stowell M, Hyde T, Robbins M.  Therapeutic role of a psychiatric intensive care unit in acute psychosis.  Comprehensive Psychiatry 28(3): 264-269, 1987. 

14.  Dunner DL, Myers J, Khan A, Avery D, Ishiki D, Pyke R.  Adinazolam - a new antidepressant: findings of a placebo controlled, double-blind study in outpatients           with major depression.  Journal of Clinical Psychopharmacology 7(3): 170-172, 1987. 

15.  Khan A, Cohen S, Stowell M, Capwell R, Avery D, Dunner DL.  Treatment options in severe psychotic depression.  Convulsive Therapy 3(2): 93-99, 1987. 

16.  Cohen S, Khan A, Johnson S.  Pharmacological management of manic psychosis in an

            unlocked setting.  Journal of Clinical Psychopharmacology 7(4): 261-264, 1987. 

17.  Cohen S, Khan A.  Adjunctive benzodiazepines in acute schizophrenia. Neuropsychobiology 18: 9-12, 1987. 

18.  Cohen S, Khan A.  Respiratory distress with use of lorazepam in mania.  Journal of Clinical Psychopharmacology 7(3): 199-200, 1987. 

19.  Geiduschek J, Cohen S, Khan A, Cullen BF.  Repeated anesthesia for a patient with neuroleptic malignant syndrome.  Anesthesiology 68: 134-137, 1988.

20.  Scher M, Hartford J, Khan A, Gentry R, Wilson L.  Comparison of two formats for a

            psychiatry clerkship.  Journal of Medical Education 63(2): 140-143, 1988. 

21.  Solan W, Khan A, Avery D, Cohen S.  Psychotic and nonpsychotic depression: comparison of response to ECT.  Journal of Clinical Psychiatry 49(3): 97-99, 1988.

22.  Cohen S, Khan A, Clark A, Goldner M, Dunner DL.  Hospitalization effect in acute mania.  General Hospital Psychiatry 10(2): 138-141, 1988. 

23.  Cohen S, Khan A, Robison J.  Significance of mixed features in acute mania. Comprehensive Psychiatry 29(4): 421-426, 1988. 

24.  Khan A, Johnson F, Avery D, Cohen S, Scherzo B, Dunner DL.  DST results in nonpsychotic depressed outpatients.  American Journal of Psychiatry 145(9): 1153-1156, 1988. 

25.  Khan A, Cohen S, Dager S, Avery D, Dunner DL.  Onset of response in relation to outcome in depressed outpatients with placebo and imipramines.  Journal of Affective Disorders 17(1): 33-38, 1989. 

26.  Cohen S, Khan A, Cox G.  Demographic and clinical features predictive of recovery in acute mania.  The Journal of Nervous and Mental Disease 177(10): 638-642, 1989. 

27.  Khan A, McMurray JS, McCreery JM, Hunt H. Carbamazepine and SIADH.  American

            Journal of Psychiatry 146(12): 1639, 1989. 

28.  Vitiello MV, Prinz PN, Avery DH, Williams DE, Ries RK, Bokan JA, Khan A.  Sleep is undisturbed in elderly, depressed individuals who have not sought health care.  Biological Psychiatry 27(4): 431-440, 1990. 

29.  Scher M, Briggs T, Khan A, Cohen S.  Patient satisfaction with care received in teaching

            settings.  Academic Psychiatry 12: 21-26, 1990. 

30.  Cohen S, Khan A.  The antipsychotic effect of milieu in the acute treatment of schizophrenia.  General Hospital Psychiatry 12(4): 248-251, 1990. 

31.  Healey W, Khan A, Noonan C.  Major depression with psychosis (MD-P): demographic, phenomenological, and outcome characteristics in one hospitalized population.  Journal of Nervous and Mental Disease 178: 722-723, 1990. 

32.  Dager SR, Khan A, Cowley D, Avery DH, Elder J, Roy-Byrne P, Dunner DL. Characteristics of placebo response during long-term treatment of panic disorder. Psychopharmacology Bulletin 26(3): 273-278, 1990. 

33.  Avery DH, Khan A, Dager SR, Cox G, Dunner DL.  Bright light treatment of winter depression: morning versus evening light.  Acta Psychiatrica Scandinavica 82: 335-338, 1990. 

34.  Avery DH, Khan A, Dager SR, Cohen S, Cox GB, Dunner DL.  Morning or evening

            bright light treatment of winter depression? The significance of hypersomnia.  Biological Psychiatry 29: 117-126, 1991. 

35.  Avery D, Khan A, Dager S, Cohen S, Cox G, Dunner DL.  Is morning light exposure superior to evening light in treating seasonal affective disorder?  Psychopharmacology Bulletin 26(4): 521-524, 1990. 

36.  Khan A, Dager S, Cohen S, Avery D, Scherzo B, Dunner DL.  The chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 4: 125-130, 1991. 

37.  Cohen S, Khan A, Zheng Y, Chiles J.  Tardive dyskinesis in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population.  Acta Psychiatrica Scandinavica 83: 234-237, 1991. 

38.  Khan A, Fabre L, Rudolph R. Venlafaxine in depressed outpatients.   Psychopharmacology Bulletin 27(2): 141-144, 1991. 

39.  Khan A, Brown WA.  Who should receive antidepressants: suggestions from placebo treatment.  Psychopharmacology Bulletin 27(3): 271-274, 1991. 

40.  Khan A, Noonan C, Healey W.  Is a single tricyclic antidepressant trial an active treatment for psychotic depression?  Progress in Neuropsychopharmacology and Biological Psychiatry 15(6): 765-770, 1991. 

41.  Khan A, Shim H, Mirolo MH, Horita A, Douglas R, Tucker GJ.  TRH effects on arousal, locomotor activity and spontaneous alternation in ECS post-ictal state. 

            Psychopharmacology 106: 570-571, 1992. 

42.  Davis JM, Janicak PG, Khan A.  Neuroleptic Malignant Syndrome.  In: Dunner DL, ed., Current Psychiatric Therapy, WB Saunders, Philadelphia, Pennsylvania, 170-175, 1992. 

43.  Goren A, Swindell C, Khan A.  Expressive language characteristics of schizophrenic subjects with different medication histories.  Journal of Neurolinguistics 7(1): 67-90, 1992.

44.  Khan A, Mirolo HA, Mirolo MH.  Depression in the elderly: A treatable disorder.  Geriatrics 48(suppl 1): 14-17, 1993.

45.  Khan A, Mirolo MH, Claypoole K, Hughes D.  Low dose TRH effects in cognitively impaired alcoholics.  Alcoholism: Clinical and Experimental Research 17(4): 791-796, 1993.

46.  Khan A, Mirolo MH, Hughes D, Bierut L.  Electroconvulsive Therapy.  Psychiatric Clinics of North America 16(3): 497-513, 1993.

47.  Khan A, Mirolo MH, Mirolo HA, Miller S.  Can ECT-induced cognitive effects be altered pharmacologically?  Progress in Neuropsychopharmacology and Biological Psychiatry 17: 861-874, 1993. 

48.  Khan A, Mirolo MH, Lai H, Claypoole K, Bierut L, Malik R, Bhang J.  ECT and TRH: Cholinergic Involement in a Cognitive Deficit State.  Psychopharmacology Bulletin 29(3): 345-352, 1993

49.  Khan A, Lai H, Ukai Y, Mirolo MH.  NS-3, a TRH-Analog, Reverses Repeated ECS Induced Deficits in Water-Maze Performance in the Rat.  Pharmacology, Biochemistry and Behavior 47(3): 477-481, 1994. 

50.  Brown WA and Khan A.  Which Depressed Patients Should Receive Antidepressants?  CNS Drugs 1(5): 341-347, 1994.  

51.  Rosenfarb IS, Becker J, Khan A.  Perceptions of parental and peer attachments by women with mood disorders.  Journal of Abnormal Psychology 103(4): 637-644, 1994

52.  Khan A, Mirolo MH, Claypoole K, Bhang J, Cox G, Horita A, Tucker GJ.  Effects of low-dose TRH in the ECT post-ictal state.  American Journal of Psychiatry 151 (11): 1694-1696, 1994

53.  Rosenfarb IS, Becker J, Khan A, Mintz J.  Dependency, self-criticism, and perceptions of socialization experiences.  Journal of Abnormal Psychology 103(4): 669-675, 1994

54.  Khan A, Lai H, Nishimura Y, Mirolo MH, Singh NP.  Effect of ECS on DNA single-strand breaks in rat brain cells.  Convulsive Therapy 11(2): 114-121, 1995

55.  Singh NP and Khan A.  Acetaldehyde: geno- and cytotoxicity in human lymphocytes. 

            Mutation Research 337: 9-17, 1995

56.  Khan A, Rudolph R, Baumel B, Ferguson J, Ryan PJ, Shrivatsava R.  Venlafaxine in depressed geriatric outpatients: an open-label clinical study.  Psychopharmacology Bulletin 31(4): 753-758, 1995.    

57.  Singh NP, Graham, MM, Singh V, Khan A.  Induction of DNA single-strand breaks in human lymphocytes by low doses of gamma rays.  International Journal of Radiation Biology 68(5): 563-569, 1995. 

58.  Singh NP, Lai H, Khan A.  Ethanol-induced single-strand DNA breaks in rat brain cells.  Mutation Research 345(3-4): 191-196, 1995.   

59.  Khan A. Overall safety profile of venlafaxine: a commentary.  Journal of Clinical

            Psychopharmacology 16(suppl 2): 59S-61S, 1996

60. Chandos B, Khan A, Lai H, Lin JC.  In: Ueno E, ed.  The application of electromagnetic energy to the treatment of neurological and psychiatric diseases.  Biological effects of magnetic and electromagnetic fields, Plenum Press, NY,  pp.161-169, 1996. 

61.  Khan A.  Letter to the Editor (Antidepressant Discontinuation Syndrome), Psychiatric Annals 27: 259, 1997.

62.  Lehman AK, Ellis B, Becker J, Rosenfarb I, Devine R, Khan A, Reichler R.  Personality and depression: a validation study of the Depressive Experiences Questionnaire.  Journal of Personality Assessment 68(1): 197-210, 1997

63.  Khan A, Upton, GV, Rudolph R, Entsuah R, Leventer SM and venlafaxine investigator study group.  The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: A dose-response study.  Journal of Clinical Psychopharmacology 18(1): 19-25, 1998. 

64.    Rosenfarb IS, Becker J, Khan A, Mintz J.  Dependency and self-criticism in bipolar and unipolar depressed women. British Journal of Clinical Psychology 37: 409-414, 1998.

65.    Khan A.  Treating Depression.  Psychiatric Annals 29(3): 123-124, 1999. 

66.    Khan A, Warner H, Brown, WA.  Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the FDA database.  Archives of General Psychiatry  57: 311-317, 2000. 

Invited Commentaries by Drs. Leber, Michels, Quitkin, Klein, Hirschfeld, Chmura Kramer, Leon.  Archives of General Psychiatry 57: 319-330, 2000. 

Cited in New York Times.  Erica Goode.  More fuel for debate on Prozac.  OL.CXLIX,

No. 51; 369, Tuesday, April 25, 2000

Cited in Science.  Martin Enserink.  Are placebo-controlled drug trials ethical?  Science 288: 5465, April 21, 2000, p. 416.

Cited in WebMD.  Amy Rothman Schonfeld.  Analysis of FDA data indicates placebo-treated patients not at increased risk for suicide compared with active controls-experts debate the role of placebo-controlled trials.  April 17, 2000. 

Cited in Science News.  Bruce Bower.  Placebos for depression attract scrutiny, 157: April

29, 2000, p.278.  

67.   Cohen S, Glazewski R, Khan S, Khan A.  Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.  Journal of Clinical Psychiatry 62(2): 114-116, 2001.

68.  Khan A, Brown WA.  The placebo enigma in antidepressant clinical trials.  Invited Guest Editorial.  Journal of Clinical Psychopharmacology 21(2): 123-125, 2001.    

69.  Khan A, Khan S, Leventhal R, Brown W.  Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration database.  International Journal of Neurpsychopharmacology 4: 113-118, 2001.

70.  Khan A, Khan S, Leventhal RM, Brown WA.  Symptom reduction and suicide risk among

            patients treated with placebo in antipsychotic clinical trials: an analysis of the FDA

            database.  American Journal of Psychiatry 158(9): 1449-1454, 2001.

71.  Khan A, Leventhal RM, Khan S, Brown WA.  Severity of depression and response to antidepressants and placebo: An analysis of the FDA database.  Journal of Clinical

            Psychopharmacology 22(1): 40-45, 2002. 

72.  Khan A, Leventhal RM, Khan S, Brown WA.  Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database.  Journal of Affective Disorders 68: 183-190, 2002.  

73.  Khan A, Khan S, Leventhal RM, Krishnan R, Gorman J.  An application of the revised

            CONSORT standards to FDA summary reports of recently approved antidepressants and

            antipsychotics.  Biological Psychiatry 52 (1): 62-67, 2002.   

74.  Khan A, Leventhal RM.  Medical aspects of capital punishment executions.  Journal of

            Forensic Science  47(4): 847-851, 2002. 

75.  Khan A, Khan S, Brown WA.  Are placebo controls necessary to test new antidepressants and anxiolytics?  International Journal of Neuropsychopharmacology 5: 193-197, 2002. 

76.  Khan A, Khan SR, Shankles EB, Polissar NL.  Relative sensitivity of the Montgomery-

            Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical

            Global Impressions rating scale in antidepressant clinical trials.  International Clinical

            Psychopharmacology 17(6): 281-285, 2002. 

77.  Cohen S, Fitzgerald B, Okos A, Khan S, Khan A.  Weight, lipid, glucose and behavioral measures with ziprasidone treatment in a population with mental retardation.  Journal of

            Clinical Psychiatry 64(1): 60-62, 2003.  

78.  Khan A, Khan S.  Placebo in mood disorders: the tail that wags the dog.  Current

            Opinion in Psychiatry 16: 35-39, 2003. 

79.  Khan A, Khan SR, Walens G, Kolts R, Giller EL.  Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: An analysis of the Food and Drug Administration Summary Basis of Approval reports.  Neuropsychopharmacology 28:

            552-557, 2003. 

80.  Khan A, Detke M, Khan S, Mallenkrodt C.  Placebo response and antidepressant clinical trial outcome.  Journal of Nervous and Mental Disease 19(4): 211-218, 2003.

81.  Khan A, Khan S, Kolts R, Brown WA.  Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: Analysis of FDA reports.  American Journal of Psychiatry

            160(4): 790-792, 2003.

82.  Storosum J, van Zweiten B, Wohlfarth T, de Haan L, Khan A, van der Brink W.  Suicide risk in placebo versus active treatment in placebo-controlled trials for schizophrenia.  Archives of General Psychiatry 60(4): 365-368, 2003. 

83.  Cohen SA, Fitzgerald BJ, Khan S, Khan A.  The effect of a switch to Ziprasidone in an   adult population with autistic disorder: Chart review of naturalistic, open-label treatment.  Journal of Clinical Psychiatry 65(1): 110-113, 2004.

84.  Robinson D, Khan A.  Dosing strategies for antidepressant clinical trials: A commentary (Editorial).  Journal of Clinical Psychopharmacology 24(1): 1-3, 2004. 

85.  Khan A, Brodhead AE, Kolts RL.  Relative sensitivity of the Montgomery-Asberg Depression rating Scale, the Hamilton Depression rating Scale and the Clinical

            Global Impressions rating scale in antidepressant clinical trials.  International Clinical

            Psychopharmacology 19: 157-160, 2004. 

86.  Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of Venlafaxine ER in adult outpatients with generalized social anxiety disorder.  Journal of Clinical Psychopharmacology 24(5): 488-496, 2004.

87.  Khan A, Kolts RL, Thase ME, Krishnan KR, Brown WA.  Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.  American Journal of Psychiatry, 160(11): 2045-2049, 2004.

88.  Khan A, Ginsberg LD, Asnis GM, Goodwin FK, Davis KH, Kishnan AA.  Effect of

             Lamotrigine on cognitive complaints in patients with bipolar I disorder.  Journal of

            Clincial Psychiatry, 65 (11): 1483-1490, 2004.

89.  Labellarte M, Biederman J, Emslie G, Ferguson J, Khan A, Ruckle J, Sallee R, Riddle M. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents.  Journal of the American Academy of Child and Adolescent Psychiatry, 43(12):  1497 – 1505, 2004.

90.  Khan A, Brodhead AE, Kolts RL, Brown WA.  Severity of depressive symptoms and response to antidepressants and placebo in antidepressant clinical trials.  Journal of

            Psychiatric Research, 39(2): 145-150, 2005.

91.  Khan  A, Kolts RL, Rapaport MH, Krishan KR, Brodhead AE, Brown WA.  Magnitude of placebo response and drug placebo differences across psychiatric disorders. Psychological Medicine, 35(5): 743-749, 2005.

92.  Khan A, Schwartz K.  Study designs and outcome in antidepressant clinical trials.  Essential

            Psychopharmacology, 6(4): 221 – 226, 2005.

93.  Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA.  Sex differences in antidepressant response among outpatients participating in antidepressant clinical trials. Journal of Clinical Psychopharmacology, 25(4):  318-324, 2005.

            Cited in Consumer Reports on Health. Drug Safety: His and Hers. December 2005.

94.  Khan A, Schwartz K.  Design features that affect psychopharmacology trials.  Letters in Drug Design & Disocvery, 2(7): 546-550, 2005.

95.  DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G. Mifepristone vs Placebo in the treatment of psychosis in patients with psychotic major depression.  Biological Psychiatry, 60(12) 1343-9, 2006.

96.  Khan A, Brodhead AE.  Fixed and flexible dosing strategies among antidepressant clinical trials.  Salud Mental, 9(1): 4-5, 2005.

97.  Khan A, Kolts RL, Brodhead AE, Krishnan KR, Brown WA.  Suicide risk analysis among patients assigned to psychotropics and placebo.  Psychopharmacology Bulletin, 39(1): 6-14, 2006.

98.  Khan A, Stern C. Design features, patient characteristics associated with antidepressant clinical trial outome.  Sociedad Iberoamericana de Informacion Cientifica, Nov. 2006.

99. Khan A, Schwartz KA, Kolts RL, Brown W.  BMI, sex, and antidepressant response. Journal of Affective Disorders, 99(1-3): 101-106, 2007.

100. Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C.  Relationship between depression severity entry criteria and antidepressant clinical trial outcomes.  Biological Psychiatry, 62(1): 65-71, 2007.

101.  Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese J, BOLDER II Study Group.  Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study).  Journal of Clinical Psychopharmacology, 26(6): 600-609, 2006.

102.  Thase ME, Shelton RC, Khan A. Treatment of SSRI nonresponders with venlafaxine extended release: a randomized comparison of standard and higher dosing strategies.  Journal of Clinical Psychopharmacology, 26(3): 250-258, 2006.

103.  Khan A, Schwartz K.  Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA Summary Basis of Approval reports.  Annals of Clinical Psychiatry, 19(1): 1-6, 2007.

104.  Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E.  Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. Journal of Clinical Psychiatry, 68(1): 58-68, 2007.

105.  Alper K, Schwartz KA, Kolts RL, Khan A.  Seizure risk incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.  Biological Psychiatry, 62(4): 345-54, 2007.

106.  Khan A, Schwartz K, Kolts RL, Redding N, Brown, WA.  Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports. Neuropsychopharmacology, 32(11): 2422-30, 2007.

107.  Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.  Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.  Clinical Drug Investigation, 27(7): 481-492, 2007.

108.  Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A.  The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.  Journal of Clinical Psychiatry, 68(6): 843-853, 2007.

109.  Khan A, Schwartz K, Stern C, Redding N, Kolts RL, Brown WA, Robinson D.  Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. Journal of Clinical Psychiatry, 68(12): 1828-1833, 2007.

110.  Ridgway D, Khan A, Ridgway G, Cierpial MA, Linebery CG.  Subject numbers and placebo outcome variability in clinical trials of new CNS medications.  Drug Information Journal, 41: 701-709, 2007.

111.  Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus  N, Owen R.  Aripiprazole monotherapy in non-psychotic bipolar I depression: results of two randomized, placebo-controlled studies.  Journal of Clinical Psychopharmacology 28(1): 13-20, 2008.

112.  Khan A, Redding N, Brown WA.  The persistence of the placebo response in antidepressant clinical trials.  Journal of Psychiatric Research. 42: 791-796, 2008.

113.  Nelson JC, Thase ME, Khan A.   Are antidepressants effective? What’s a Clinician to think? J Clinical Psychiatry 69: 1014-1015, 2008.

114.  Khan A, Khan S.  Placebo response in depression: a perspective for clinical practice.       Psychopharmacology Bulletin 41(3): 91-98, 2008.

115.  Khan A.  Current evidence for aripiprazole as augmentation therapy in major depressive disorder.  Expert Reviews of Neurotherapeutics 8(10): 1435-1447, 2008    

116.  Gelenberg A, Thase M, Meyer R, Goodwin F, Katz M, Kraemer H, Potter W, Shelton R,

            Fava M, Khan A et al.  The history and current state of antidepressant clinical trial design: a call to action for proof – of – concept studies.  Journal of Clinical Psychiatry 69: 1513- 1528, 2008. 

117.  Khan A, Bhat A.  Is the problem of a high placebo response unique to antidepressant trials?  Journal of Clinical Psychiatry 69: 1979-1980, 2008. 

118.  Khan A.  Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.  Expert Opinion on Investigational Drugs 18: 1-12, 2009.

119.  Hale M, Khan A, Kutch M, Li S.  Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients chronic low back pain.  Current Medical Research and Opinion 26: 1505-1518, 2010.

120.  Khan A, Bomminayuni EP, Bhat A, Faucett J, Brown W.  Are the colors and shapes of current psychotropics designed to enhance the placebo response?  Psychopharmacology 211: 113-122, 2010. 

121.  Khan A, Bhat A, Kolts R, Thase M, Brown W. Why has the antidepressant – placebo difference in antidepressant clinical trials diminished over the past three decades?  CNS Neuroscience & Therapeutics 16: 217-226, 2010. 

122.  Schwartz JRL, Khan A, McCall V, Weintraub J, Tiller J.  Tolerability and efficacy of armodafinil in patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: a 12-month open-label study with an extension period. Journal of Clinical Sleep Medicine 6: 450-457, 2010.

123.  Khan A, Bhat A, Faucett J, Kolts R, Brown W.  Antidepressant-placebo differences in 16 clinical trials over 10 years at a single site: role of baseline severity.  Psychopharmacology 214: 961-965, 2010.

124.  Marcus R, Khan A, Rollin L, Morris B, Timko K, Carson W, Sanchez R.  Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar 1 disorder with an inadequate response to lithium or valproate monotherapy: A multi-center, double-blind, randomized study.  Bipolar Disorders 13: 133-144, 2011.

125.  Weisler RH, Khan A, Trivedi MH, Yang H, Eudicone JM, Pikalov A, Quynh-Van Tran, Berman RM, Carlson BH.  Analysis of suicidality in pooled data from two double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder: Journal of Clinical Psychiatry 72:548-555, 2011.

126.  Khan A, Cutler AJ, Kajdasz D, Athanasiou M, Robinson DS, Whalen H, Reed CR.  Efficacy and tolerability of vilazodone, a dual acting serotonergic antidepressant, in the treatment of patients with major depressive disorder (MDD). Journal of Clinical Psychiatry 72:441-447, 2011.

127.  Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H.  A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.  Journal of Clinical Psychopharmacology 31: 418-428, 2011.

128.  Khan A, Faucett J, Emslie G, Brown W.  Comparison of Efficacy and Safety Measures Between Pediatric and Adult Clinical Trials for Bipolar Mania Based on Food and Drug Administration Summary Basis of Approval Reports. Israili Journal of Psychiatry: In Press.

 

129.  Khan A, Khan SRF, Hobus J, Faucett J, Mehra V, Giller E, Rudolph R.  Changes in suicide risk measures and depressive symptoms with lithium combined with citalopram compared to citalopram with placebo in severely ill and suicidal depressed patients: A randomized, double-blind trial. Journal of Psychiatric Research:  In Press.

 

 

Current Projects

 

Khan A, Faucett J, Lichtenberg P, Kirsch I, Brown WA.  Pattern of response to four established depression treatments and four controls based on 188 depression treatment trials including 24,108 depressed patients:  Role of blinding.  In Development.

Khan A, Atkinson S, Mezhebovsky I, She F, Leathers T, Pathak S. Extended release quetiapine fumarate (Quetiapine XR) as adjunct therapy in patients with generalized anxiety disorder and a history of inadequate response: A randomized, double-blind study. Under Review.

Webster LR, Michna E, Khan A, Israel RJ, Manley A, Zhang H, Maller E, Tzanis E. Long-term safety of methylnaltrexone for treatment of opioid-induced constipation in nonmalignant pain.  In Development.

Delbello MP, Hochadel TJ, Blanchard K, Mehra S, Katic A, Khan A, Emslie G.  A double-blind, placebo-controlled study of selegiline transdermal system (STS) in depressed adolescents.  Poster Presentation Submitted for American Academy of Child and Adolescent Psychiatry, October 2011 Annual Meeting.

Khan A. Pharmacokinetic evaluation of vilazodone for the treatment of depression. In Development.

Hale ME, Nalamachu SR, Khan A.  Gastrointestinal tolerability during conversion and titration with once-daily hydromorphone ER (OROS hydromorphone ER) in opiod-tolerant patients with chronic low back pain.  Abstract Submission for Pain Week, September 2011.

Hale ME, Nalamachu SR, Khan A.  Gastrointestinal tolerability during conversion and titration with once-daily hydromorphone ER (OROS hydromorphone ER) in opiod-tolerant patients with chronic low back pain.  Abstract Submission for NAPA Pain Conference, September 2011.

Delbello MP, Hochadel TJ, Blanchard K, Mehra S, Katic A, Khan A, Emslie G.  A double-blind, placebo-controlled study of selegiline transdermal system (STS) in depressed adolescents.  Poster Presentation Submitted for ACNP, December 2011 Annual Meeting.

129.  Khan A, Khan SRF, Hobus J, Faucett J, Mehra V, Giller E, Rudolph R.  Changes in suicide risk measures and depressive symptoms with lithium combined with citalopram compared to citalopram with placebo in severely ill and suicidal depressed patients: A randomized, double-blind trial. Poster Presentation Submitted for ACNP, December 2011 Annual Meeting.

 

 

 

Abstracts, Book Reviews, and Other Publications:

 

1.   Khan A, Johnson GA and Becker JT.  Catecholamine turnover with ECT.  14th Annual Meeting of Society for Neuroscience (Abstract, p. 289, Part I), 1984. 

2.   Becker JT, Khan A, Reddy AS.  Hypothalamic amnesia in man.  14th Annual Meeting of Society for Neuroscience (Abstract, p. 385, Part I), 1984. 

3.   Khan A, Lee E, Dager S, Hyde T, Raisys V, Avery D, Dunner DL.  Platelet MAO-B activity in anxiety and depression.  IV Congress in Biological Psychiatry (Abstract p. 90), 1985.

4.   Dager S, Khan A, Comess K, Raisys V, Dunner DL.  MHPG/creatinine, MAO-B activity,

            autonomic arousal and MVP in anxious patients.  Annual Meeting of  Society of Biological Psychiatry (Abstract, p. 106), 1986. 

5.   Khan A, Cohen S, Chiles J, Dunner DL.  Therapeutic role of a psychiatric care unit in acute psychosis. Annual Meeting of Society of Biological Psychiatry (Abstract, p. 37), 1987. 

6.   Khan A, Hyde T and Dunner DL.  Treatment response to placebo and IMI/DMI in outpatients with major depression.  Annual Meeting of Society of Biological Psychiatry (Abstract, p. 243), 1987. 

7.   Khan A, Cohen S, Avery D, Dunner DL.  Treatment options in psychotic depression.. Annual Meeting of Society of Biological Psychiatry (Abstract, p. 242), 1987. 

8.   Avery D, Khan A, Dager S, Dunner DL.  Temperature rhythm phase-typing of seasonal

            affective disorder and response to Am and PM bright light.  Annual Meeting of the Sleep

            Research Society (Abstract), 1987.

9.   Nelson WH, Khan A.  Age effects on the dexamethasone suppression test in unipolar major depression.  Neuroendocrinology letters; 9:181, 1987. 

10.  Khan A, Dunner DL.  Clinical predictors of placebo response in depressed outpatients. 

            Panel presentation at 26th Annual Meeting of American College of

            Neuropsychopharmacology (Abstract, p. 58), 1987. 

11.  Avery D, Khan A, Cohen S.  Bright light treatment of SAD: AM vs PM light.  Symposium at World Psychiatric Association Washington, DC (Abstract), 1988. 

12.  Khan A. Acute treatment of psychotic depression.  Clinical Advances in the Treatment of

            Psychiatric Disorders 2; 4: 4, 1988.                                                   

13.  Khan A, Dunner DL.  Study group participant on placebo response at the 27th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 56), 1988. 

14.  Cohen S, Khan A.  Hospitalization effect on acute exacerbation of schizophrenia.  Schizophrenia Research  2: 220, 1989. 

15.  Khan A, Dager S, Dunner DL.  Clinical and demographic features related to placebo and

            antidepressant response.  Biological Psychiatry 25:79-80A, 1989, (Suppl). 

16.   Khan A.  Book Review on "Electroconvulsive Therapy" by Richard Abrams, MD, 1988.  Journal of Nervous and Mental Disease 177:501-502, 1989. 

17.   Khan A.  Study group participant on placebo response in depression at the 28th Annual Meeting of the American College of Neuropsychopharmacology, (Brown and Dunner, Abstract, p. 44), 1989. 

18.   Khan A, Dager S, Cohen S, Avery D, Dunner DL.  When is the onset of response to antidepressant?  28th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 198), 1989. 

 

19.   Dager S, Khan A, Cowley DC, Avery DH, Elder J, Roy-Byrne P, Dunner DL.  Clinical

            characteristics of placebo response among panic patients.  28th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 183), 1989. 

20.   Cohen S, Khan A, Cox G.  Demographic and clinical features predictive of recovery in

            acute mania.  Psychiatry Digest 6:23-25, 1990. 

21.   Khan A and Brown WA.  Who should receive antidepressants: suggestions from placebo

            treatment.  29th Annual Meeting of the American College of Neuropsychopharmacology,

            (Abstract, p. 138) December, 1990. 

22.   Khan A, Mirolo MH, Horita A, Lampe T, Tucker GJ.  TRH in ECT/ECS post-ictal   state.  30th Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 233), 1991. 

23.   Khan A, Lai H, Mirolo MH, Ukai Y.  TRH and ECT: Cholinergic involvement in cognitive deficit state.  31st Annual Meeting of the American College of Neuropsychopharmacology, (Abstract, p. 106) 1992. 

24.   Khan A.  Book review on "Electroconvulsive Therapy" by Richard Abrams, Second Edition.  Journal of Nervous and Mental Disease; 181:592, 1993. 

25.   Khan A, Steiert J, Githens S.  Effective collaboration with managed care.  146th Annual Meeting of the American Psychiatric Association, (Issue Workshop #12, Abstract   p. 303-304), 1993. 

26.   Khan A, Mirolo MH, Claypoole K, Lai H, Tucker G.  Low-dose TRH effects in       ECT post-ictal state.  Annual Meeting of the Society of Biological Psychiatry (Abstract, p 654), 1994. 

27.   Khan A, Lai H, Nishimura Y, Mirolo MH, Singh NP.  ECS effects on neuronal DNA strand breaks.  Annual Meeting of the Society of Biological Psychiatry (Abstract, p. 664), 1994. 

28.   Singh NP, Malik S, Kenny MA, Lai H, Khan A.  Acetaldehyde induced DNA single strand breaks in human lymphocytes.  Annual Meeting of the Society of Biological Psychiatry (Abstract, p. 708), 1994. 

29.   Khan A, Rudolph R, Baumel B, Ferguson J, Ryan P, Shrivatsava R, Mirolo MH.  Venlafaxine in depressed geriatric outpatients: an open label study.  XIXth CINP Congress (Abstract, p. 163S), 1994. 

30.   Ferguson J, Khan A, Kucharik R, Leventer S, and Cucci C.  A placebo-controlled comparative study of the effects on blood pressure and antidepressant efficacy of venlafaxine and imipramine.  XIXth CINP Congress (Abstract, p. 165S), 1994. 

31.   Khan A, and Montgomery N.  Seizure Inhibition Syndrome.  Annual Meeting of the

            Association for convulsive Therapy (Abstract in Convulsive Therapy, p. 70), 1995. 

32.   Khan A. Overall safety profile of venlafaxine: a commentary.  An invited abstract for

            Psychiatry Digest, February (Abstract p. 27-28), 1997

33.   Khan A.  Panel Participant: IMGs and ABPN Performance, APA Annual meeting (p. 36) 1997. 

34.   Khan A, Warner H and Brown WA.  Placebo in Antidepressant Clinical trials:  Efficacy and safety.  36th Annual Meeting of the American College of Neuropsychopharmacology (Abstract p.138). December, 1997.

35.     Khan A, (Chair) Brown WA (Moderator) and Quitkin F (ACNP Invitee).  Are placebo

            controls ethical in antidepressant clinical trials?  Study Group at the 37th Annual Meeting

            of the American College of Neuropsychopharmacology, 1998

36.     Cookson J, Khan A, Asnis P et al.  Profile of antidepressant activity of lamotrigine

            (Lamictal) in Bipolar and Unipolar Depression:  Results from double-blind, placebo-

            controlled studies.  12th Annual meeting of the European College of

            Neuropsychopharmacology (Abstract), September 1999. 

37.   Efficacy of lamotrigine in bipolar and unipolar depression: results from double-blind,

            placebo-controlled studies.  Asnis G, Beaman M, Bowden C, Calabrese, De Veaugh-

            Geiss, Evoniuk G, Huffman R and Khan A.  38th Annual Meeting of the American

            College of Neuropsychopharmacology, December 1999 (Abstract p. 162). 

38.   Khan A and Khan S.  Are placebo controls ethical in antidepressant clinical trials?  Invited Article for Psychiatric Times, XVII: 4 – 29, April 2000. 

39.   Khan A, Warner H,  Brown WA.  Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials.  Archives of General Psychiatry, April, 2000, vol. 57, © American Medical Association. pp 311-317 (see also pages 319, 321, 323, 325, 327 & 329)

40.   Huffman R, Ascher J, Khan A, and Calabrese J.  Evaluation of efficacy and safety of

             lamotrigine for the long-term treatment of bipolar depression.  New Clinical Drug Evaluation Unit (NCDEU), poster #51, 2000. 

41.   Earl N, Greene P, Ascher J, Fouche N, Chang C, Evoniuk G, Swann A, Pope S, Ketter T, McElroy S, Post R, Zajecka J, Altshuler L, Apter J, Wets S, Risch C, Khan A.  Mood stabilization with lamotrigine in rapid cycling bipolar disorder.  European College of Neuropsychopharmacology (ECNP) Annual Meeting, Munich, September, 2000. 

42.   Labetelle M, Zumbrunnen T, Brennan J, Biederman J, Connor J, Emslie G,Ferguson J, KhanA, Ruckle J, Sallee R, Riddle M. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. Child Neuropsychiatry Conference (Pisa), poster, May, 2000.

43.   Khan A, Khan S, Leventhal R, Brown WA.  Symptom reduction and suicide risk among

            patients treated with placebo in antipsychotic clinical trials: an analysis of the FDA

            database.  39th Annual meeting of the American College of Neuropsychopharmacology

            (Abstract #178), 2000.

44.   Suppes T, Altshuler L, Apter J, Bowden C, Calabrese J, Ginsberg L, Goldberg J, Gyulai L, Khan A, McElroy S, Rapaport M, Risch S, Scahs G, Swann A, West S, Zajecka J, Ascher J, Barrows C, Earl N,Greene P.  Mood stabilization with lamotrigine in rapid cycling bipolar disorder:  a double-blind placebo-controlled study.  39th Annual meeting of the American College of Neuropsychopharmacology (Abstract #99), 2000.

45.   Khan A, Khan SR, Brown WA.  Do psychotropics reduce suicide risk?  40th Annual Meeting of the American College of Neuropsychophamacology (Abstract #159, p. 186), 2001

46.   Pollock MH, Feltner, DE, Rickels K, Lydiard RB, Zimbroff DL, Bieski RJ, Khan A,

            Goodrich J, Brock JD, Pande AC.  A placebo-controlled, double-blind study of

            pregabalin treatment of generalized anxiety disorder.  40th Annual Meeting of the

            American College of Neuropsychopharmacology (Abstract #46, p. 337), 2001. 

47.   Bowden C, Ghaemi N, Gyulai L, Huey L, Khan A, Montgomery P, Ascher, J. 

            Lamotrigine delays mood episodes in recently depressed bipolar I patients.  Annual meeting of the American Psychiatric Association, 2002.

48.   Khan A, Khan S, Walens G, Giller E.  Frequency of positive studies among fixed and flexible dose antidepressant clinical trials:  An analysis of the Food and Drug Administration Summary Basis of Approval reports.  41st Annual Meeting of the

            American College of Neuropsychopharmacology (poster), 2002.

49.   Khan A, Khan S, Kolts R, Brown WA.  Suicide rate with SSRI antidepressants compared to other antidepressants and placebo.  41st Annual Meeting of the American College of Neuropsychopharmacology (poster), 2002.

50.   Khan A, Khan S, Kolts R, Brown WA.  Research design factors associated with antidepressant clinical trial outcome.  New Clinical Drug Evaluation Unit,          May 2003. 

51.   Khan A, Kolts R, Brown WA.  Research Design Features associated with antidepressant   clinical trial outcome.  42nd Annual meeting of the American College of Neuropsychopharmacology, 2003.

52.   Khan A, Brodhead AE, Kolts RL, Brown WA.  Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale, and the Clinical Global Impressions Rating Scale in antidepressant clinical trials.  New Clinical Drug Evaluation Unit, poster #174, June 2004.

53.   Khan A, Brodhead AE, Kolts RL, Brown WA.  Severity of depressive symptoms and response to antidepressants and placebo in antidepressant clinical trials.  New Clinical Drug Evaluation Unit, poster #176, June 2004.

54.   Khan A, Brodhead AE, Lai H, Singh NP.  Commercial potential of toxins, developing toxins for applications in drug discovery and diagnostics.  International Society on Toxinology- European Section, 15th European Symposium on Animal, Plant and Microbial Toxins, June 2004. 

55.   Khan A, Schwartz TL.  Tiagabine as an efficacious augmentation therapy to selective serotonin reuptake inhibitors in patients with generalized anxiety disorder.  17th European College of Neuropsychopharmacology, October 2004.

56.   Khan A, Brodhead AE, Kolts RL, Brown WA.  Sex differences in SSRI antidepressant response among outpatients participating in antidepressant clinical trials.  43rd Annual meeting of American College of Neuropsychopharmacology, December 2004. 

57.   Khan A, Schwartz KA, Kolts RL, Brodhead AE, Brown WA.  Sex differences and BMI in relation to antidepressant clinical trial outcomes.  New Clinical Drug Evaluation Unit, June 2005.

58.   Khan A, Schwartz KA.  Clinical trials: 20-year trends and predictors of success.  New

            Clinical Drug Evaluation Unit, June 2005.

59.   Khan A, Alper K, Schwartz K, Kolts R, Brown W.  Seizure risk among patients

            participating in psychopharmacology clinical trials.  Annual Meeting of the

            American College of Neuropsychopharmacology (poster), December 2005.

60.   Khan A, Schwartz K, Kolts R, Alper K, Stern C, Krishnan R, Brown W.  Frequency of suicides, suicide attempts, seizures, and mortality in psychopharmacological clinical trials.  APA Lunch Forum: Hot Topics in Psychopharmacology and Drug Safety.  Annual Meeting of the American Psychiatric Association, May 2006.

61.   Khan A, Farfel GM, Brock JD, Kavousi R, Chatamra K.  Efficacy and safety of pregabalin for the treatment of generalized anxiety disorder in elderly patients.  Annual Meeting of American Psychiatric Association (poster), May 2006.

62.   Khan A, Schwartz K, Kolts R, Alper K, Stern C, Krishnan R, Brown W.  Seizure, suicide, and mortality among psychiatric patients based on FDA SBA reports.  Annual Meeting for New Clinical Drug Evaluation Unit (poster), June 2006.

63.   Khan A, Schwartz K, Kolts R, Alper K, Stern C, Krishnan R, Brown W.  Frequency of suicides, suicide attempts, seizures, and mortality in psychopharmacological clinical trials.  Enhancing precision in clinical trials: recruitment, study design, measurement, endpoints.  Annual Meeting for New Clinical Drug Evaluation Unit, June 2006.

64.   Khan A, Schwartz K, Kolts RL, Ridgway D, Redding N, Lineberry C.  Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Annual Meeting of the American College of Neuropsychopharmacology (poster), December 2006.

65.   Brown WA, Redding N, Kolts RL, Khan A.  The persistence of the placebo response in antidepressant clinical trials. Annual Meeting of the American College of Neuropsychopharmacology (poster), December 2006.

66.   Cohen SA, Redding N, Petras A, Khan A.  Clinician weight as a factor in prescribing atypical antipsychotics. Annual Meeting of the American Psychiatric Association (APA), poster NR374, May 2007.

67.   Khan A, Redding N.  Mortality rates in antipsychotic and antidepressant clinical trials: evaluating short and long-term safety for CNS agents.  Annual Meeting for New Clinical Drug Evaluation Unit (NCDEU), June 2007

68.   Brown WA, Solomon DA, Khan A.  Book review on “Handbook of Contemporary Neuropharmacology” by Sibley D, Hanin I, Kuhar M, Skolnick P (eds). JAMA 298(22): 2682-2683, 2007.

67.     Khan A, Bhat A.  Failed antidepressant trials: causes and solutions.  Annual Meeting for   

             New Clinical Drug Evaluation Unit (poster), June 2008.

69.   Khan A, Bhat A, Kolts R, Thase M, & Brown W.  Decrease in antidepressant placebo        differences over time is associated with changes in research design features.  Annual   Meeting of the American College of Neuropsychopharmacology (poster), November 2008.

70.   Khan A, Bhat A, Kolts R.  Vilazodone – efficacy and safety evaluation from a single center.   Annual Meeting for New Clinical Drug Evaluation Unit (poster), June 2009. 

71.   Khan A, Bhat A, Kolts R, Brown W.  Does maintaining baseline severity of depressive symptoms over time affect antidepressant – placebo differences?  Annual Meeting of the American College of Neuropsychopharmacology (poster), December 2009. 

72.   Khan A, Cutler AJ, Kajdasz D, Athanasiou M, Robinson DS, Whalen H, Reed CR.  Efficacy and tolerability of vilazodone, a dual-actin serotonergic antidepressant, in the treatment of patients with major depressive disorder.  Annual Meeting of the American Psychiatric Association, poster NR42, May 2010.

73.   Owen R, Rollin L, Khan A, Sanchez R, Carson W, Morris B, Timko K, Marcus R.  Efficacy of adjunctive aripiprazole to lithium or valproate in the long-term treatment of mania in subjects with bipolar 1 disorder.  Annual Meeting of the American Psychiatric Association (presentation), May 2010.

74.   Khan A, Bhat A, Faucett J, Kolts R, Brown W.  Antidepressant-placebo differences over an eleven year period in a sample of patients with high and similar baseline scores.  Annual Meeting for New Clinical Drug Evaluation Unit (poster), June 2010.

75.   Abbar M, Owen R, Rollin L, Khan A, Sanchez A, Carson W, Morris B, Timko K, Marcus RN.  Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of mania in subjects with bipolar 1 disorder.  23rd Meeting of the European College of Neuropsychopharmacology (poster), August, 2010.

76.  Khan AInvited Commentary on: Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population based nested case-control study by Bandrup et al.  Evidence Based Mental Health; 13:90 doi:10.1136/ebmh.13.3.90, 2010.

77.  Khan A, Faucett J, Brown W, Emslie G.  Comparison of Efficacy and Safety Measures Between Pediatric and Adult Clinical Trials for Bipolar Mania Based on Food and Drug Administration Summary Basis of Approval Reports.  49th Annual Meeting for the American College of Neuropsychopharmacology.  December, 2010.

78.  Abbar M, Khan A, Rollin LM, Sanchez R, Carson W, Morris B, Timko K, Marcus RN.  Efficacy of adjunctive aripiprazole to lithium or valproate in the long-term treatment of mania in subjects with bipolar 1 disorder. 19th European Congress of Psychiatry (poster), Prague, Czeck Republic, March 2011.

79.  Khan A., Rutherford B., Sinyor, M., Mischoulon, D., Brown, W.  Why do antidepressant trials fail?  Symposium Chair and presentation for the 2011 APA Conference in Honolulu, HI.  May, 2011.

80.  Webster L, Michna E, Khan A, Manley A, Zhang H, Tzanis E, Maller E.  The long-term safety of subcutaneous methylnaltrexone for the treatment of opiod-induced constipation in patients with chronic non-malignant pain.  Annual Meeting for the American Pain Society (poster).  Austin, TX, May 2011.

81.  Webster L, Michna E, Khan A, Israel R, Manley A, Zhang H, Maller E, Tzanis E.  Subcutaneous methylnaltrexone provides long-term laxation in patients with chronic non-malignant pain and opioid-induced constipation.  Annual Meeting for the American Pain Society (poster).  Austin, TX, May 2011. 

82.  Khan A, Faucett J, Lichtenberg P, Brown W.  Placebo control in antidepressant trials: A misnomer.  Annual Meeting for the New Clinical Drug Evaluation Unit (poster), Boca Raton, FL, June 2011. Nominated for Best Poster and Invited for 2011 NCDEU Online CME Poster Presentation.

83.  Khan A, Khan SRF, Hobus J, Faucett J, Mehra V, Giller E, Rudolph R.  Changes in suicide risk measures and depressive symptoms with lithium combined with citalopram compared to citalopram with placebo in severely ill and suicidal depressed patients: A randomized, double-blind trial. Annual Meeting for the New Clinical Drug Evaluation Unit (poster), Boca Raton, FL, June 2011.

84.  Khan A.  Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar 1 disorder with an inadequate response to lithium or valproate monotherapy: A multi-center, double-blind, randomized study.  Podcast for Journal of Bipolar Disorder. In Press

85.  Hale ME, Nalamachu SR, Khan A.  Gastrointestinal tolerability during conversion and titration with once-daily hydromorphone ER (OROS hydromorphone ER) in opiod-tolerant patients with chronic low back pain.  Pain Week (poster), September 2011.

86.  Hale ME, Nalamachu SR, Khan A.  Gastrointestinal tolerability during conversion and titration with once-daily hydromorphone ER (OROS hydromorphone ER) in opiod-tolerant patients with chronic low back pain.  NAPA Pain Conference (poster), September 2011.

87.  Delbello MP, Hochadel TJ, Blanchard K, Mehra S, Katic A, Khan A, Emslie G.  A double-blind, placebo-controlled study of selegiline transdermal system (STS) in depressed adolescents.  American Academy of Child and Adolescent Psychiatry Annual Meeting (poster), October, 2011.

88.  Khan A, Khan SRF, Hobus J, Faucett J, Mehra V, Giller E, Rudolph R.  Changes in suicide risk and depressive symptoms with low dose lithium combined with citalopram compared to citalopram with placebo in a group of severely ill depressed patients. 50th Annual Meeting for the American College of Neuropsychopharmacology (poster), Waikaloa, HI, December, 2011.

89.  Delbello MP, Hochadel TJ, Blanchard K, Mehra S, Katic A, Khan A, Emslie G.  A double-blind, placebo-controlled study of selegiline transdermal system (STS) in depressed adolescents.  50th Annual Meeting for the American College of Neuropsychopharmacology (poster), Waikaloa, HI, December, 2011.

90. Khan A, Faucett J, Garimella R, Oquendo MA, Weisler R, Patkar AA.  Completed Suicides in the United States between 1979 and 2007: Relationship to Age, Sex and Antidepressant Prescription Patterns.  Annual Meeting of the American Psychiatric Association (poster), May 2012.

91. Khan S, Faucett J, Khan A. Role of patient characteristics, research design features, and mechanism of action of medication on clinical trial outcome of FDA approved medications for attention-deficit hyperactivity disorder: A review of publication bias free data of 3,843 patients. Annual Meeting for the New Clinical Drug Evaluation Unit (poster), June 2012.

92  Litman RE, Symialis S, Khan A.  Are large numbers of investigative sites associated with symptom improvement on placebo in antipsychotic randomized controlled trials: A meta-analytic review. Annual Meeting for the New Clinical Drug Evaluation Unit (presentation), May, 2012 Annual Meeting.

93. Khan A, Song W, Edwards J, Ruth A.  A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms.  Annual Meeting of the American Psychiatric Association (Poster), May, 2012.

94. Khan A, Song W, Edwards J, Ruth A.  A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms.  Annual Meeting of the New Clinical Drug Evaluation Unit (Poster), May, 2012.

95. Khan A, Song W, Edwards J, Ruth A.  A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms.  Annual Meeting of the CINP World Congress of Psychopharmacology (Poster), June, 2012.

96. Khan A, Song W, Edwards J, Ruth A.  A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms.  Annual Meeting of the American Psychiatric Association Insitute on Psychiatric Services (Poster), August, 2012.

97. Khan A, Song W, Edwards J, Ruth A.  A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms.  Annual Meeting of the European College of Neuropsychopharmacology (Poster), October, 2012.

98. Khan A, Song W, Edwards J, Ruth A.  A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms.  Annual Meeting of the European College of Neuropsychopharmacology (Poster), October, 2012.

99. Khan A, Song W, Edwards J, Ruth A.  A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms.  U.S. Psychiatric and Mental Health Conference (Poster), November, 2012.

100. Edwards J, Khan A, Song W, Ruth A.  The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder.  Annual Meeting of the American Psychiatric Association (Poster), May, 2012.

101. Edwards J, Khan A, Song W, Ruth A.  The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder.  Annual Meeting of the New Clinical Drug Evaluation Unit (Poster), May, 2012.

102. Edwards J, Khan A, Song W, Ruth A.  The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder. 

103. Edwards J, Khan A, Song W, Ruth A.  The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder.  Annual Meeting of the CINP World Congress of Psychopharmacology (Poster), June, 2012.

104. Edwards J, Khan A, Song W, Ruth A.  The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder.  Annual Meeting of the American Psychiatric Association Insitute on Psychiatric Services (Poster), August, 2012.

105. Edwards J, Khan A, Song W, Ruth A.  The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder.  Annual Meeting of the European College of Neuropsychopharmacology (Poster), October, 2012.

107. Khan A, Ninan PT, Ramey T, Messig M, Buckley G, Musgnung J.  Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients for 24 weeks with desvenlafaxine 50mg/d.  Annual Meeting of the American Psychiatric Association (Poster), May, 2012.

108. Khan A, Ninan PT, Ramey T, Messig M, Buckley G, Musgnung J.  Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients for 24 weeks with desvenlafaxine 50mg/d.  Annual Meeting of the Canadian Psychiatric Association (Poster), September, 2012.

109. Nalamachu S, Hale M, Khan A. Hydromorphone extended-release in chronic neuropathic pain. PAINWeek 2012 National Conference on Pain for Frontline Practicioners (Poster), September, 2012.

110. Nalamachu S, Hale M, Khan A. Hydromorphone extended-release in chronic neuropathic pain.  Annual Clinical Meeting of the American Academy of Pain Management (Poster), September, 2012. 

111. Bakish D, Gommoll C, Chen C, Greenberg WM, Nunez R, Liebowitz M, Khan A.  Levomilnacipran SR 40 mg and 80 mg in Major Depressive Disorder: A Phase III, Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Study.  Annual Meeting of the American College of Neuropsychopharmacology (Poster), December 2012.

112. Khan A, Faucett J, Brown W. Differential outcome in Antidepressant Trials Among Raters from One Research Center (n=6) in Relation to Structured Interview Adherance Based on Outside Reviewer Evaluations. Annual Meeting of the New Clinical Drug Evaluation Unit (Poster), 2013..

 

 

 

Scheduled Poster Presentations

 

Edwards J, Khan A, Song W, Ruth A. The Clinical Relevance of Results Achieved With Vilazodone in the Treatment of Major Depressive Disorder. Poster Presentation Schedule for AMDA, CPNP, AANP
(03/21/2013)..

Khan A, Song W, Edwards J, Ruth A. A Pooled Analysis of Vilazodone in the Treatment of Major Depressive Disorder: Efficacy Across Symptoms. Poster Presentation Schedule for 2013: AMDA, SGIM..

 

 

 

Last Edited: July 1, 2013

«NWCRC Home»